Pomalidomide dosing and most common causes of dose modification
| . | Safety population (N = 676) . |
|---|---|
| Median pomalidomide treatment duration, mo (range) | 4.9 (0.1-28.3) |
| Median pomalidomide relative dose intensity* | 0.901 |
| Overall discontinuation of pomalidomide due to AE, n (%) | 40 (5.9) |
| Due to thrombocytopenia | 5 (0.7) |
| Due to pneumonia | 4 (0.6) |
| Dose reduction of pomalidomide due to AE, n (%) | 149 (22.0) |
| Due to neutropenia | 40 (5.9) |
| Due to thrombocytopenia | 29 (4.3) |
| Due to fatigue | 17 (2.5) |
| Due to pneumonia | 16 (2.4) |
| Dose interruption of pomalidomide due to AE, n (%) | 448 (66.3) |
| Due to neutropenia | 153 (22.6) |
| Due to thrombocytopenia | 75 (11.1) |
| Due to pneumonia | 69 (10.2) |
| . | Safety population (N = 676) . |
|---|---|
| Median pomalidomide treatment duration, mo (range) | 4.9 (0.1-28.3) |
| Median pomalidomide relative dose intensity* | 0.901 |
| Overall discontinuation of pomalidomide due to AE, n (%) | 40 (5.9) |
| Due to thrombocytopenia | 5 (0.7) |
| Due to pneumonia | 4 (0.6) |
| Dose reduction of pomalidomide due to AE, n (%) | 149 (22.0) |
| Due to neutropenia | 40 (5.9) |
| Due to thrombocytopenia | 29 (4.3) |
| Due to fatigue | 17 (2.5) |
| Due to pneumonia | 16 (2.4) |
| Dose interruption of pomalidomide due to AE, n (%) | 448 (66.3) |
| Due to neutropenia | 153 (22.6) |
| Due to thrombocytopenia | 75 (11.1) |
| Due to pneumonia | 69 (10.2) |
Relative dose intensity, dose intensity/planned dose intensity.